Announcements Trials
Browse Landscape

Phase

Phase 2 69Phase 1 42Phase 1/2 34Phase 3 22Phase EARLY_PHASE1 2Phase 2/3 2Phase NA 1Phase 4 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cisplatin 22Fluorouracil 21Radiotherapy 18Gemcitabine 17Docetaxel 16Oxaliplatin 15Paclitaxel 14Carboplatin 13Capecitabine 13Bevacizumab 13Leucovorin 11Cyclophosphamide 11Irinotecan 10Drug Therapy 10Cytarabine 9Saline Solution 7Magnetic Resonance Spectroscopy 7Letrozole 7Dexamethasone 7Rituximab 6Nivolumab 6Methotrexate 6Exercise 6Etoposide 6Electroporation 6Doxorubicin 6pembrolizumab 5Pemetrexed 5Metformin 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × Bendamustine Hydrochloride × Clear all
NCT02763319 2025-07-17

B-MIND

Incyte Corporation

Phase 2/3 Completed
453 enrolled 29 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01423032 2011-08-25

Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2/3 Completed
96 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡